Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Visx PRK laser

This article was originally published in The Gray Sheet

Executive Summary

Company submits two-year follow-up data to FDA for its Twenty/Twenty excimer laser for the treatment of myopia via photorefractive keratectomy. The firm submitted a premarket approval application for the device in June 1993. In addition, the firm says that FDA has asked the company for more information on its pending application for use of the Twenty/Twenty in phototherapeutic keratectomy. In response to a panel request, Visx submitted one-year follow up data on PTK patients in May



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts